A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

Bibliography

• Ingall T. Stroke: incidence, mortality, morbidity and risk. J Insur Med 2004;36(2):143-52
   PubMedGoogle Scholar
• Lloyd-Jones D, Adams R, Carnethon M, Heart disease and stroke statistics: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):480-6
   PubMed Web of Science ®Google Scholar
• The Internet Stroke Center: stroke statistics. Available from: http://www.strokecenter.org/patients/stats.htm. [Last accessed 17 May 2010]
   Google Scholar
• Petty GW, Brown RD Jr, Whisnant JP, Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31(5):1062-8
   PubMed Web of Science ®Google Scholar
• Petty GW, Brown RD Jr, Whisnant JP, Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30(12):2513-6
   PubMed Web of Science ®Google Scholar
• Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11(11):1623-32
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Fiebach JB, Mohr A, Thrombolytic therapy for ischemic stroke: review. Part II: tra- arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med 2001;29(9):1819-25
   PubMed Web of Science ®Google Scholar
• Schellinger PD, Fiebach JB, Mohr A, Thrombolytic therapy for ischemic stroke: a review. Part I: Intravenous thrombolysis. Crit Care Med 2001;29(9):1812-8
   PubMed Web of Science ®Google Scholar
• Verstraete M. Newer thrombolytic agents. Ann Acad Med Singapore 1999;28(3):424-33
   PubMedGoogle Scholar
• Hacke W, Kaste M, Bluhmki E, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
   PubMed Web of Science ®Google Scholar
• Bluhmki E, Chamorro A, Davalos A, Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009;8(12):1095-102
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 2010;1(2):96-107
   Google Scholar
• Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22(9):391-7
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 2007;12(1):97-112
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998;18(6):667-82
   PubMed Web of Science ®Google Scholar
• Love S. Oxidative stress in brain ischemia. Brain Pathol 1999;9(1):119-31
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 2008;26(2):101-14
   PubMed Web of Science ®Google Scholar
• Yoshida H, Yanai H, Namiki Y, Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006;12(1):9-20
   PubMedGoogle Scholar
• Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222(3):236-45
   PubMed Web of Science ®Google Scholar
• Nakashima M, Niwa M, Iwai T, Uematsu T. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med 1999;26(5-6):722-9
   PubMed Web of Science ®Google Scholar
• Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005;39(7):841-52
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM. Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev 2003;9(3):253-62
   PubMedGoogle Scholar
• Siesjo BK, Katsura K, Zhao Q, Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. J Neurotrauma 1995;12(5):943-56
   PubMed Web of Science ®Google Scholar
• Siesjo BK, Siesjo P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996;13(3):247-68
   PubMed Web of Science ®Google Scholar
• Lee BJ, Egi Y, van Leyen K, Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 2010;1307:22-7
   PubMed Web of Science ®Google Scholar
• Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opin Pharmacother 2009;10(2):323-31
   PubMed Web of Science ®Google Scholar
• Kono H, Woods CG, Maki A, Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage. Free Radic Res 2006;40(6):579-88
   PubMed Web of Science ®Google Scholar
• Banno M, Mizuno T, Kato H, The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology 2005;48(2):283-90
   PubMed Web of Science ®Google Scholar
• Shichinohe H, Kuroda S, Yasuda H, Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res 2004;1029(2):200-6
   PubMed Web of Science ®Google Scholar
• Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 2006;1(1):85-93
   PubMedGoogle Scholar
• Yoshida H, Sasaki K, Namiki Y, Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis 2005;179(1):97-102
   PubMed Web of Science ®Google Scholar
• Amemiya S, Kamiya T, Nito C, Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 2005;516(2):125-30
   PubMed Web of Science ®Google Scholar
• Xiao B, Bi FF, Hu YQ, Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats. Neurotox Res 2007;12(3):155-62
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Kawahara K, Tancharoen S, The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 2009;329(3):865-74
   PubMed Web of Science ®Google Scholar
• Zhang N, Komine-Kobayashi M, Tanaka R, Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005;36(10):2220-5
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Yoshida H, Metoki N, Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. Neurosci Res 2007;59(4):406-12
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Tancharoen S, Matsuda F, Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 2009;390(4):1121-5
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kuroda Y, Yamashita S, Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008;39(2):463-9
   PubMed Web of Science ®Google Scholar
• Yagi K, Kitazato KT, Uno M, Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;40(2):626-31
   PubMed Web of Science ®Google Scholar
• Kano T, Harada T, Katayama Y. Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurol Res 2005;27(5):499-502
   PubMed Web of Science ®Google Scholar
• Oishi R, Itoh Y, Nishibori M, Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain. Stroke 1989;20(11):1557-64
   PubMed Web of Science ®Google Scholar
• Nishi H, Watanabe T, Sakurai H, Effect of MCI-186 on brain edema in rats. Stroke 1989;20(9):1236-40
   PubMed Web of Science ®Google Scholar
• Jin YJ, Mima T, Raicu V, Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res 2002;43(1):75-9
   PubMed Web of Science ®Google Scholar
• Nito C, Kamiya T, Amemiya S, The neuroprotective effect of a free radical scavenger and mild hypothermia following transient focal ischemia in rats. Acta Neurochir Suppl 2003;86:199-203
   PubMedGoogle Scholar
• Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268(3):1597-604
   PubMed Web of Science ®Google Scholar
• Wu TW, Zeng LH, Wu J, Fung KP. MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci 2000;67(19):2387-92
   PubMed Web of Science ®Google Scholar
• Tanahashi N, Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med 2002;41(5):337-44
   PubMed Web of Science ®Google Scholar
• Wang CX, Shuaib A. Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 2007;24(7):537-46
   PubMed Web of Science ®Google Scholar
• Kitagawa Y. Edaravone in acute ischemic stroke. Intern Med 2006;45(5):225-6
   PubMed Web of Science ®Google Scholar
• Abe K. Edaravone. Nippon Rinsho 2006;64(Suppl 7):548-53
   PubMedGoogle Scholar
• STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30(12):2752-8
   PubMed Web of Science ®Google Scholar
• Chehrazi BB, Seibert JA, Kissel P, Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 1989;24(3):355-60
   PubMed Web of Science ®Google Scholar
• Gross CE, Raymond SJ, Howard DB, Bednar MM. Delayed tissue-plasminogen activator therapy in a rabbit model of thromboembolic stroke. Neurosurgery 1995;36(6):1172-7
   PubMed Web of Science ®Google Scholar
• Phillips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. AJNR Am J Neuroradiol 1988;9(5):899-902
   PubMed Web of Science ®Google Scholar
• Phillips DA, Fisher M, Smith TW, Davis MA. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol 1988;23(4):391-4
   PubMed Web of Science ®Google Scholar
• Zivin JA, Fisher M, DeGirolami U, Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230(4731):1289-92
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004;185(1):154-9
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 2009;215(1):95-100
   PubMed Web of Science ®Google Scholar
• Lapchak PD, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15 lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 2007;150(3):585-91
   PubMed Web of Science ®Google Scholar
• Broderick JP, Lu M, Kothari R, Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000;31(10):2335-41
   PubMed Web of Science ®Google Scholar
• Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000;31(4):811-6
   PubMedGoogle Scholar
• Lyden P, Brott T, Tilley B, Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994;25(11):2220-6
   PubMed Web of Science ®Google Scholar
• Lyden P, Lu M, Jackson C, Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 1999;30(11):2347-54
   PubMed Web of Science ®Google Scholar
• Otomo E. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15(3):222-9
   PubMed Web of Science ®Google Scholar
• Otomo E. Late phase 2 clinical trial of MCI-186 on acute cerebral infarction: a dose-finding double-blind study. J Clin Exp Med 1998;185:841-63
   Google Scholar
• Otomo E, Tohgi H, Kogure K, Clinical efficacy of a free radical scavenger, MCI-186, on acute cerebral infarction: Early phase II clinical trial. Ther Res 1998;19:1311-32
   Google Scholar
• Inatomi Y, Takita T, Yonehara T, Efficacy of edaravone in cardioembolic stroke. Intern Med 2006;45(5):253-7
   PubMed Web of Science ®Google Scholar
• Mishina M, Komaba Y, Kobayashi S, Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir (Tokyo) 2005;45(7):344-8; discussion 8
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial (TOAST) Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35-41
   PubMed Web of Science ®Google Scholar
• Ohta Y, Takamatsu K, Fukushima T, Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med 2009;48(8):593-6
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 2009;27(5):485-92
   PubMed Web of Science ®Google Scholar
• Sinha MK, Anuradha HK, Juyal R, Edaravone in acute ischemic stroke, an Indian experience. Neurol Asia 2009;14:7-10
   Web of Science ®Google Scholar
• Toyoda K, Fujii K, Kamouchi M, Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004;221(1-2):11-7
   PubMed Web of Science ®Google Scholar
• Hacke W, Schwab S, Horn M, ‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53(4):309-15
   PubMedGoogle Scholar
• Unno Y, Katayama M, Shimizu H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment?: a retrospective study of edaravone therapy. Clin Drug Investig 2010;30(3):143-55
   PubMed Web of Science ®Google Scholar
• Shibata H, Shigenori A, Izawa M, Phase I clinical study of MCI-186 (Edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in healthy volunteers: safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 1998;29(6):863-76
   Google Scholar
• Lapchak PA, KcKim JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic\ neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Res 2010; In press
   PubMed Web of Science ®Google Scholar
• Risk/benefit assessment of drugs analysis and response. Available from: http://www.rad-ar.or.jp. [Last accessed 17 May 2010]
   Google Scholar
• Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007;11(4):292-6
   PubMedGoogle Scholar
• Hishida A. Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clin Exp Nephrol 2009;13(2):118-22
   PubMed Web of Science ®Google Scholar
• Abe M, Kaizu K, Matsumoto K. A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. Ther Apher Dial 2007;11(3):235-40
   PubMed Web of Science ®Google Scholar
• Mishina M, Komaba Y, Kobayashi S, Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism. Neurol Med Chir (Tokyo) 2008;48(7):292-7
   PubMed Web of Science ®Google Scholar
• Yoshifumi T. Benefits of Pre-treatment with edaravone in tPA intravenous therapy for acute cerebral infarction. XXIII International Symposium on Cerebral Blood Flow [abstract]. J Cereb Blood Flow Metab 2007;(Suppl 1):BP34-06M
   Google Scholar
• Safety and pharmacokinetics of MCI-186 in subjects with acute ischemic stroke. Available from: http://www.clinicaltrials.gov/ct2/show/. [Last accessed 17 May 2010]
   Google Scholar
• Kageyama M, Toriyama S, Tsuboshita A. A post-marketing drug use survey of a neuroprotective drug Radicut injection 30mg (nonproprietary name: edaravone) for acute ischmic stroke. J New Rem Clin 2009;58:1212-26
   Google Scholar
• Shuaib A, Lees KR, Lyden P, NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-71
   PubMed Web of Science ®Google Scholar
• Bath PM, Gray LJ, Bath AJ, Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009;157(7):1157-71
   PubMed Web of Science ®Google Scholar